Oscotec completes Phase I study for novel osteoporosis drug

Published: 2010-02-10 06:56:00

Updated: 2010-02-10 06:56:00

Oscotec Inc. says it has successfully completed Phase I clinical trial of a novel anti-bone resorbing small molecule “OCT-1547” in the Netherlands, to evaluate safety, tolerability and pharmacokinetics as an orally administered therapeutic agent for the treatment of osteoporosis.

OCT-1547 is u...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK